The Technical Bulletin website will be updated in April 2026. Preview the new website.
Read more about the modernization release schedule in this announcement.
Contact the NLM Help Desk with any questions or concerns.
Read more about the modernization release schedule in this announcement.
Contact the NLM Help Desk with any questions or concerns.
October 25, 2011 [posted]
New Clinical Alert Issued by National Heart, Lung, and Blood Institute (NHLBI)
The National Heart, Lung, and Blood Institute (NHLBI) issued a new Clinical Alert on October 21, 2011:
NHLBI has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns. The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine (NAC) had worse outcomes than those who received placebos or inactive substances.
Links to Clinical Alerts/Advisories can also be found from these NLM® Web sites:
- A complete list of all Clinical Alerts/Advisories is available from the NIH Clinical Alerts and Advisories page on the NLM Web site.
- MedlinePlus® features Clinical Alerts/Advisories as NIH Press Releases on the appropriate Health Topics page(s).
- PubMed®, the NLM Gateway and ClinicalTrials.gov each have access points to the Clinical Alerts/Advisories.
New Clinical Alert Issued by National Heart, Lung, and Blood Institute (NHLBI). NLM Tech Bull. 2011 Sep-Oct;(382):e15.
